NCT03301298View on ClinicalTrials.gov

Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 11, 2017

Primary Completion Date

February 13, 2018

Study Completion Date

February 13, 2018

Conditions
Healthy
Interventions
DRUG

SXC-2023

Oral capsule

DRUG

Placebo oral capsule

Placebo given as oral capsule.

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Collaborators (1)

Celerion
All Listed Sponsors
collaborator

Celerion

INDUSTRY

lead

Promentis Pharmaceuticals, Inc.

INDUSTRY

NCT03301298 - Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers | Biotech Hunter | Biotech Hunter